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Introduction
There is a demonstrated increased risk of reported suicidal 
thoughts or behaviors in active or daily smokers compared 
to those who have never smoked.2,4–7 Suicidality is a general 
term that refers to a variety of behaviors, including suicidal 
ideation, suicide attempts, and successful completion of sui-
cide.1 We use the term suicidality in this manuscript to refer 
to any of these events. Suicidality can be assessed by using 
standardized measures, self-report of behaviors, or other doc-
umentation of ideation, behaviors, attempts, or completed sui-
cide. People who smoke have a twofold to threefold increased 
risk of suicide.3,4
The link between active smoking and increased suicidal-
ity risk, although strong and reliable, is still not well under-
stood and is explored in detail in other reviews (eg, Hughes1). 
Our primary focus is on increased risk of suicidality during 
smoking cessation, and thus, we will only briefly mention the 
proposed associations between active smoking and suicidality. 
Active smoking may be associated with increased suicide risk 
due to shared confounding variables that are correlated with 
both suicide and smoking, including mood symptoms such 
as depression, anxiety, and emotional lability.8 The underly-
ing mechanism for this increased risk is unclear, although 
confounding by alcohol misuse and mental illness seems to 
explain some, but certainly not all, of the association.1 Two 
epidemiological studies support a direct positive relationship 
between smoking/nicotine dependence and suicide after con-
trolling for a number of possible confounding mental health 
disorders.9,10 The first of these studies9 found that nicotine 
dependence was one of only four diagnoses that indepen-
dently accounted for a high proportion of suicide attempts 
(the other three disorders were major depressive disorder, bor-
derline personality disorder, and post-traumatic stress disor-
der). The second study10 found that nicotine dependence was 
associated with suicide attempts, independent of all Axis I 
and Axis II conditions as well as physical diseases. Addition-
ally, Yaworski et al.10 recently found that previously nicotine-
dependent individuals who have abstained for at least one year 
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were significantly less likely to attempt suicide than people 
still dependent on nicotine, which suggests a direct role of 
nicotine dependence on suicidality. Kendler et al.11 have also 
produced research demonstrating shared genes that contrib-
ute to increased likelihood of both smoking and depression. 
Smoking leads to a physical dependence on nicotine and often 
causes serious physical illnesses, which has also been hypoth-
esized to lead to an increased risk of suicide.12 Once addicted, 
an individual’s attempts to quit smoking, in the face of seri-
ous illness or otherwise, can result in withdrawal symptoms, 
including irritability, headaches, weight gain, and insomnia.13 
Nicotine withdrawal symptoms may also be accompanied 
by depressed mood in some individuals.14 The risk of suicide 
is increased by the presence of psychological factors such as 
depression, anxiety, emotional instability, and antisocial per-
sonality.15 Some have hypothesized that quitting smoking 
may precipitate depression, which may increase the risk of 
suicide.16 Because risk factors tend to overlap, smoking may 
be conceptualized as a way of self-medicating to abate these 
symptoms.17 Nicotine has been demonstrated to help regulate 
mood and reduce negative effects that may reduce anxious 
and impulsive symptoms, thus potentially reducing suicidal-
ity risks.18 Smoking cessation may also contribute to suicide 
risk because an important coping mechanism (ie, smoking) 
is removed. Definitive causal links are challenging to make 
because many of the risk factors for suicide are associated with 
risk factors for smoking.12,19
The link between various forms of medications to help 
quit smoking and increased suicidality risk is equally con-
founding. Part of the challenge is that there are multiple 
interventions available to aid with smoking cessation, and 
they work in differing ways. Pharmacological options include 
bupropion, varenicline, and various forms of nicotine replace-
ment therapy. Some of the pharmacotherapies may carry an 
increased risk of suicide,20 although not all of the research 
supports this.21 Nonpharmacological approaches include cog-
nitive and/or behavioral therapy (referred to also as behav-
ioral psychotherapy) and approaches involving mindfulness 
training. Cognitive behavioral therapies have been shown to 
increase success rates and may mitigate suicide risk during 
smoking cessation.22 In this paper, we review both the suicide 
risks associated with and the effectiveness of nicotine replace-
ment therapies, other commonly prescribed smoking cessation 
pharmacotherapies, cognitive behavioral psychotherapies, and 
mindfulness strategies.
Methods
We obtained information by searching Ovid and PubMed 
for articles related to smoking cessation and suicidality. Spe-
cific terms included smoking cessation, nicotine dependence, 
varenicline, bupropion, nicotine replacement, cognitive 
behavi oral therapy, mindfulness, and contextual cognitive 
behavioral therapy, each crossed with suicide, suicidality, and 
suicidal ideation. We then selected specific manuscripts based 
on the appropriateness and applicability of each to the topic. 
We focused on smoking cessation treatment in people who 
are actively smoking and did not include relapse prevention 
studies or purely educational programs. Additional manu-
scripts were obtained from appropriate references cited in 
these  manuscripts as well as references in the public domain 
obtained from pharmaceutical companies and regulatory 
agencies. A total of ∼100 manuscripts were reviewed and 
information from 92 was included in this review based upon 
the authors’ judgments.
Pharmacotherapies for smoking cessation
Pharmacotherapy for smoking cessation primarily targets 
reducing nicotine withdrawal symptoms and cravings in order 
to help people stop smoking. Nicotine withdrawal symptoms 
experienced by smokers include headache, nausea, anxiety, 
depression, and many other psychological and physiological 
discomforts.13 The general mechanisms of drug therapies for 
smoking cessation work by blocking nicotine from binding to 
its receptor and enhancing the release of neurotransmitters.23 
Some medications such as varenicline and nicotine replace-
ment medications may also have an agonistic effect.24,25 The 
inhibition of nicotine aids in alleviating withdrawal symp-
toms and cravings as the reinforcing effects of nicotine are 
diminished.20 Although many have reported success in sig-
nificantly reducing tobacco consumption or quitting smok-
ing with pharmacological therapies such as bupropion and 
varenicline, these medications can have side effects, and there 
is some support that they may increase depressive symptoms 
and/or risk for suicidality, which must be considered when 
prescribing.26,27
The potential increased risk of suicidality observed in 
some reports of pharmacotherapies for smoking cessation 
is a concern. In 2009, the US Food and Drug Association 
added warning labels on manufactured smoking aids alert-
ing a possible association between suicidal behaviors and the 
usage of bupropion and varenicline.28 The warning high-
lighted an increased risk of psychiatric symptoms such as 
agitation, hostility, depressed mood, and most importantly, 
increased occurrences of suicidal behaviors. Observed in the 
post-marketing reports, patients with no history of psychi-
atric disorders reported suicidal thoughts and an increase of 
suicidal ideation and behaviors after using these products.28 
When recommending prescription drugs for addiction treat-
ment, it is vital to weigh the possible adverse or even poten-
tially life-threatening effects against the potential benefits to 
ensure the health and safety of the patient. We review the pre-
dominant types of smoking cessation pharmacotherapies cur-
rently researched: nicotine replacement therapies, bupropion, 
and varenicline.
Nicotine replacement therapies. Nicotine replace-
ment therapies (NRTs) are licensed as first-line treat-
ments for smoking cessation both in the United States and 
Europe.29 NRT was the first effective pharmacotherapy for 
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treatment of nicotine dependence and is currently avail-
able without a medical prescription. It is marketed as a 
transdermal patch in various dosages, which provides slow 
absorption through the skin, or as a nasal/buccal absorp-
tion product (chewing gum, lozenges, sublingual tablets, 
nasal sprays, and inhalers).20,29
NRTs help people quit smoking by reducing the cravings 
to smoke and both the physiological and psychological with-
drawal symptoms that can be experienced during and after 
quitting. NRTs have also been shown to reduce the reinforc-
ing effects of smoking.20 A 2013 Cochrane review, covering 
267 studies and involving 101,804 participants who explored 
multiple pharmacotherapies for smoking cessation, found 
NRT to be superior to placebo, helping ∼80% more people 
to quit than placebo (odds ratios (ORs) of 1.84 (95% CredI 
1.71−1.99). In other words, for every 10 people who quit with 
placebo, ∼18 were expected to quit with NRT.
Efficacy was defined as sustained abstinence at least six 
months after smoking cessation. In head-to-head compari-
sons, individual NRTs were equally effective among the dif-
ferent formulations and also equally effective to bupropion. 
Varenicline was more effective for sustained smoking cessa-
tion than either bupropion or a single NRT, but equally effec-
tive when compared to combined NRTs.29
Moore et al.28 examined case reports of adverse events 
reported to the United States Food and Drug Administration 
(US FDA) for NRTs, varenicline, and bupropion for smoking 
cessation. The NRT group (including all routes of adminis-
tration) was used as a comparison group for the varenicline 
and bupropion. An additional comparison group included 
combined case reports for three commonly used antibiotics. 
This antibiotic comparison group was established to assess the 
underlying risks that might be attributed to the smoking ces-
sation population independent of study drugs, in a population 
not seeking to stop smoking. The main outcome measure was 
the ratio of reported suicide/self-injury or depressions cases 
for each drug compared to all other serious events for that 
drug. The authors identified 3,249 reported cases of suicidal/
self-injurious behavior or depression overall. They found a 
higher number of reports of suicidality/self-injurious behavior 
among patients using NRTs (N = 50) compared to those using 
antibiotics (N = 21). Of note, there were 40 cases of suicidal 
ideation, 2 attempts, 1 indication of suicidal behavior, 1 indi-
cation of intentional self-injury, 4 intentional overdoses, and 
4 completed suicides in the NRT group. There were seven cases 
of suicidal ideation, seven attempts, zero indication of suicidal 
behavior, one indication of intentional self-injury, eight inten-
tional overdoses, and three completed suicides in the com-
parison antibiotic medication group. Moore et al.28 concluded 
that using NRTs for smoking cessation may be associated with 
higher risk of suicidality.28 However, the evidence supporting 
their conclusion is somewhat limited, as they did not include 
a comparison group of individuals attempting to quit smoking 
without any pharmacotherapy. Additionally, both varenicline 
and bupropion were observed to have far higher numbers of 
individuals who experienced suicidal ideation (N = 1135 and 
N = 73), attempts (N = 323 and N = 56), behaviors (N = 63 and 
N = 1), and completions (N = 272 and N = 19) than individuals 
who were taking NRTs.
Thomas et al.21 also compared the risk of suicide, self-
harm, and depression in patients prescribed varenicline or 
bupropion with those prescribed nicotine replacement the-
rapy in a prospective cohort study within the Clinical Prac-
tice Research Datalink. Outcomes were treated depression 
and fatal as well as non-fatal self-harm within three months 
of the first smoking cessation prescription. Hazard ratios 
or risk differences were estimated using Cox multivariate 
regression models, propensity score matching, and instru-
mental variable analysis. These researchers reported 92 
cases of suicide and non-fatal self-harm and 1,094 records 
of treated depression at three months of follow-up after the 
date of treatment initiation. Six of these suicides were in the 
NRT group and two in the varenicline group. In contrast 
to the findings of Moore et al.28, Thomas et al.21 found no 
evidence that patients prescribed varenicline had a higher 
risk of fatal or non-fatal self-harm (hazard ratio: 0.88; 95% 
confidence interval: 0.52−1.49) or treated depression (haz-
ard ratio: 0.75; 95% confidence interval: 0.65−0.87) than 
patients prescribed NRTs and also demonstrated no evidence 
that patients prescribed bupropion had a higher risk of fatal 
or non-fatal self-harm (hazard ratio: 0.83; 95% confidence 
interval: 0.30−2.31) or treated depression (hazard ratio: 0.63; 
95% confidence interval: 0.46−0.87) than patients prescribed 
NRTs. Thus, Thomas et al.21 concluded that their research 
did not support an increased risk of suicidality or depres-
sion in patients prescribed varenicline or bupropion versus 
NRTs. In fact, in their basic model, hazard ratios showed 
a lower risk of all-cause mortality (hazard ratio: 0.37; 95% 
confidence interval: 0.26−0.54) in patients prescribed varen-
icline than in those prescribed NRTs. Findings were similar 
for bupropion compared to NRT with self-harm, and sui-
cide risks were lower in bupropion versus NRT (hazard ratio: 
0.31; 95% confidence interval: 0.13−0.74) at three months. 
The results of  Thomas et al.21 are limited by the fact that 
the study was an uncontrolled cohort study, and thus many 
variables, such as adherence, the use of other medications, 
and history, could not be controlled.
Overall, it would appear that the literature reviewed 
appears to support that NRTs used for smoking cessation do 
not increase rates of suicidality any greater than bupropion or 
varenicline and that NRTs may actually demonstrate lower 
risks in this population.
bupropion sr. Bupropion SR was the first non-nicotinic 
pharmacotherapy approved for smoking cessation and was 
first licensed as an antidepressant. Bupropion is a betaphenyl-
ethylamine derivative that preferentially blocks the reuptake 
of norepinephrine and dopamine in the mesolimbic system 
and the nucleus accumbens. Although its pharmacological 
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mechanism of action in smoking cessation remains unclear, 
data from animal studies suggest that it acts as an antagonist 
at the nicotinic acetylcholinergic receptor. Therefore, it may 
work by blocking the reinforcing effects of nicotine, decreas-
ing withdrawal symptoms, and potentially reducing depressed 
mood and cigarette cravings. Given its stimulant properties 
and appetite suppression, bupropion has also been postulated as 
helpful in reducing post-smoking cessation weight gain.20,29,30 
A 2014 Cochrane review, examining evidence up to July 2013, 
evaluated 44 clinical trials and concluded that there is a high-
quality evidence base confirming the benefit of bupropion 
used as a single pharmacotherapy for smoking cessation. The 
effects were comparable across several different populations 
and settings, using different types of behavioral support, and 
in smokers regardless of past history of depression.30 A previ-
ous review had found that, similar to NRTs, bupropion helped 
about 80% more smokers quit than placebo.29
Several studies have examined the use of bupropion in 
specific populations that have higher risks associated with con-
tinued smoking. For example, Tonstad et al.31 found that more 
than twice as many smokers with cardiovascular disease who 
had been treated with bupropion SR for seven weeks had quit 
smoking at one year, compared with placebo; the safety profile 
was comparable to that observed in general smoking popula-
tions. Of note, depressed subjects were excluded for the trial, 
and worsening mood and/or depression were not specifically 
measured nor mentioned during the trial.31 In a small, double-
blind pilot study of alcohol- and nicotine-dependent patients 
(N = 11), randomized to bupropion or placebo, patients in the 
bupropion arm had a significant reduction in smoking expo-
sure and withdrawal symptoms.32 In a trial to assess smoking 
cessation among inner city African Americans, a group with 
likely higher rates of smoking and greater smoking-attributable 
morbidity and mortality, sustained smoking cessation rates 
(26 weeks) were significantly higher in patients taking bupro-
pion for 7 weeks compared with placebo. There were no signif-
icant differences in neuropsychiatric adverse events between 
both groups.33 Tashkin et al.34,99 conducted a double-blind, 
randomized, placebo-controlled trial of individuals with mild-
to-moderate chronic obstructive pulmonary disease who were 
actively smoking. Abstinence rates were significantly higher 
in those receiving bupropion than in those receiving placebo, 
after week 4, during the 12-week treatment phase, and at the 
6-month follow-up.
Post-marketing reports of neuropsychiatric effects 
(worsening depression and suicidality) led the FDA and the 
European Medicine Agency to add a black box warning to the 
labels of bupropion for smoking cessation (marketed as Zyban, 
Wellbutrin, and generics) in 2009.20 This warning high-
lighted the risk of serious neuropsychiatric symptoms such 
as changes in behavior, hostility, agitation, depressed mood, 
suicidal thoughts and behavior, and attempted suicide.35 In a 
study that analyzed the French Pharmacovigilance Database 
from 2001 to 2004 and included all spontaneous reports of 
serious adverse reactions to bupropion, Beyens et al.36 found 
that neuropsychiatric side effects like depression and suicide 
attempts were reported in a frequency similar to that of the 
general population (17.3% of the cases). The most frequently 
reported serious adverse events in the study were seizures, 
angioedema, and serum-like reactions.36 It is important to 
note that this study included data from the first three years 
after the start of marketing of bupropion SR for smoking ces-
sation and prior to the black box warning.
In their evaluation of case reports of adverse events 
reported to the FDA, Moore et al.28 found that the odds 
ratio for suicide was elevated for bupropion compared to the 
antibiotic comparison group (OR: 12.5; CI: 9.1−17.2). They 
identified 229 cases (7%) of suicidal/self-injurious behav-
ior or depression, 19 cases (6%) of completed suicides, and 
56 cases (15%) of suicide attempts associated with bupropion.28 
These findings demonstrate less risk for suicidality in those 
prescribed bupropion versus those prescribed varenicline, and 
an increased risk for suicidality in those prescribed bupropion 
than for those patients receiving NRTs (as described in the 
NRT section).
However, a number of meta-analyses of randomized 
controlled trials (RCTs) have also explored the association of 
depression and suicidality with use of bupropion for smok-
ing cessation, and found no correlation. Wightman et al.37 
analyzed data on antidepressant suicidality from RCTs using 
bupropion for multiple indications. The studies were conducted 
between 1976 and 2006, and no statistically significant differ-
ences were found between bupropion and placebo in terms of 
expressed suicidal ideation or behavior.37 A 2013 Cochrane 
review, evaluating 82 trials, also demonstrated no excess of 
neuropsychiatric or cardiovascular events in those prescribed 
bupropion.29 A 2014 Cochrane review specifically evaluat-
ing antidepressants for smoking cessation did not detect any 
difference between bupropion and placebo or no pharmaco-
therapy controls in rate of psychiatric or cardiovascular seri-
ous adverse events but detected a marginal and nonstatistically 
significant increased rate of serious adverse events in people 
randomized to bupropion.30
Overall, findings reviewed support that bupropion appears 
to be effective for many in promoting smoking cessation and 
appears to have limited and mixed support regarding the 
increased risk of suicidality with its use. Based upon research 
reviewed, bupropion also has similar risk of suicidality to pla-
cebo or no treatment and may have lower risks for suicidality 
when compared to varenicline, but may have higher rates of risk 
than NRTs.
Varenicline. Varenicline, marketed as Chantix, is the most 
recently approved pharmacotherapy for smoking cessation.38 It 
was derived from the cytisine compound and has greater bio-
availability and selectivity for alpha-4 beta-2 nicotinic receptors 
as a partial agonist. It is completely absorbed orally, not affected 
by food, and reaches steady state within 4 days of administra-
tion; its half-life is 24 hours. It has low protein binding and, 
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unlike nicotine, does not undergo hepatic metabolism. Most of 
the drug is excreted unchanged in the urine.39
As a partial agonist of the alpha-4 beta-2 nicotinic recep-
tor, varenicline stimulates receptor-mediated activity, blocking 
the ability of nicotine to activate these receptors and stimulat-
ing dopamine turnover in the nucleus accumbens (involved in 
the reward circuit and addiction) by 32%−45% of that achieved 
with nicotine. This stimulation leads to a moderate and sus-
tained increase in dopamine levels, thereby decreasing nicotine 
cravings and withdrawal symptoms present during smoking 
cessation. In those who relapse during treatment, varenicline 
also appears to reduce the rewards experienced by blocking 
nicotine-induced dopaminergic activation (antagonist action), 
which aids in abstinence.20,29,40,41
In a Cochrane review covering a total of 267 studies 
(20 specific for varenicline), Cahill et al.29 found that vareni-
cline more than doubled the odds of quitting smoking ver-
sus placebo (ie, for any 10 individuals who quit with placebo, 
28 could be expected to quit with varenicline). Head-to-head 
comparisons with other smoking cessation pharmacotherapies 
showed that varenicline was superior to single forms of NRT 
and also to bupropion; it was of equal efficacy to combination 
NRT.29 Other meta-analyses have confirmed the increased 
efficacy of varenicline on smoking cessation rates during 
12-week treatment compared with placebo and also bupro-
pion.20 In a large RCT examining bupropion SR, varenicline, 
and placebo for smoking cessation, it was found that the effi-
cacy of varenicline in the short term and long term (up to 
52 weeks) exceeded that of both placebo and bupropion SR.41
In November 2007, the US FDA first reported that 
varenicline might cause serious neuropsychiatric symptoms, 
adding information about the reported effects to the post-
marketing experience section of the prescribing information 
and also requesting that the manufacturer include this infor-
mation. In 2008, the US FDA issued a safety warning for 
healthcare professionals, advising that varenicline could have 
neuropsychiatric adverse events such as changes in behavior, 
agitation, suicidal ideation, and attempted and completed sui-
cide. A black box warning for this medication was required 
starting in 2009, based on continued post-marketing adverse 
event reports for varenicline and bupropion.26,27,35,40,42,43
Moore et al.28 found that 90% of the 3,249 FDA-reported 
cases of suicidal/self-injurious behavior or depression asso-
ciated with smoking cessation pharmacotherapies were 
found in individuals taking varenicline. This included 272 
(92%) of the reported completed suicides and 323 (85%) of 
all reported suicide attempts. The authors concluded that 
varenicline is unsuitable for first-line use in smoking cessa-
tion. Ahmed et al.40 analyzed 25 published case reports span-
ning from 2006, when varenicline received FDA approval, 
to 2012. Analysis of all reports using the Naranjo causality 
scale, a method for estimating the probability of adverse drug 
reactions, indicated probable causality in 76% of the cases and 
definite causality in 12% of the cases.
Prospective cohort studies have been performed in the 
UK without evidence that varenicline was associated with 
increased risk of serious neuropsychiatric adverse events. 
A cohort study including 80,660 adults who were prescribed 
NRT, varenicline, or bupropion between 2006 and 2008 
found no clear evidence that varenicline was associated with 
an increased risk of fatal or nonfatal self-harm or of depres-
sion.44 Thomas et al.21 identified 119,546 adults prescribed 
pharmacotherapy (varenicline, bupropion, NRT) for smoking 
cessation in primary care practices between 2006 and 2011. 
They found no evidence of increased risk of suicidal behav-
ior in patients prescribed varenicline or bupropion compared 
to those prescribed NRT. Additionally, Tonstad et al.45 in a 
pooled analysis examined the incidence of psychiatric adverse 
events in 10 completed RCTs of varenicline and that the inci-
dence of psychiatric disorders other than sleep disorders and 
disturbances was 10.7% in subjects treated with varenicline 
and 9.7% in subjects treated with placebo, with an RR of 
1.02 (95% CI: 0.86, 1.22). The RRs (95% CI) versus placebo 
of psychiatric adverse events with an incidence $1% in the 
varenicline group were 0.86 (0.67, 1.12) for anxiety disor-
ders and symptoms, 0.76 (0.42, 1.39) for changes in physical 
activity, 1.42 (0.96, 2.08) for depressed mood disorders and 
disturbances, 1.21 (0.79, 1.83) for mood disorders and distur-
bances not elsewhere classified, and 1.70 (1.50, 1.92) for sleep 
disorders and disturbances. The authors reported no cases of 
suicidal ideation or behavior in varenicline-treated subjects in 
the 10 placebo-controlled studies analyzed. However, among 
three trials that were excluded from the analysis because of 
their open-label design, two cases of suicidal ideation and 
one completed suicide were reported in patients who had 
been treated with varenicline. There was no evidence of dose 
responsivity except for the sleep disturbances.45
A UK study44 examined the association of varenicline 
and increased risk of suicide and suicidal behavior compared 
to bupropion and NRT in a cohort study nested in the General 
Practice Research Database. Gunnell et al.44 found no clear 
evidence that varenicline was associated with an increased 
risk of fatal (n = 2) or non-fatal (n = 166) self-harm, although 
a twofold increased risk cannot be ruled out on the basis 
of the upper limit of the 95% CI. Compared with nicotine 
replacement products, the hazard ratio for self-harm among 
people prescribed varenicline was 1.12 (95% CI: 0.67−1.88), 
and it was 1.17 (0.59−2.32) for people prescribed bupropion. 
There was no evidence that varenicline was associated with 
an increased risk of depression (n = 2244) (hazard ratio: 0.88 
(0.77−1.00)) or suicidal thoughts (n = 37) (1.43 (0.53−3.85)).
In the monitoring study by Kasliwali et al.46, the most 
frequently reported psychiatric events during treatment 
included (n;% of cohort) sleep disorder (43; 1.6%), anxiety (33; 
1.2%), depression (29; 1.1%), abnormal dreams (26; 1.0%), 
and mood change (17; 0.6%). Two cases of attempted sui-
cide were reported during treatment with varenicline; how-
ever, the authors reported that these patients had previous 
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history of psychiatric illness and precipitating factors for the 
event. Another monitoring study by Harrison-Woolrych and 
Ashton47 in New Zealand evaluated the occurrence rates of 
psychiatric adverse reactions in a general population pre-
scribed varenicline between April 2007 and March 2008. The 
study included 3,415 patients. They found that sleep disorders 
were the most frequently reported psychiatric events with an N 
of 56 (4.3%) patients in the responder population. Symptoms 
of depression were reported by 39 (2.98%) patients (24 new-
onset depression, 14 worsening of pre-existing depression, and 
1 report of impaired motivation). Serious psychiatric reactions 
including suicide (one case), suicidal ideation (two cases), and 
psychotic reactions (three cases) were also identified. Six self-
harm events (one fatal, five non-fatal) were identified in the 
total cohort, giving an occurrence rate of 0.18% (95% CI: 0.06, 
0.38) in this population.
The US FDA sponsored two large retrospective cohort 
studies to explore possible relationships between varenicline 
and neuropsychiatric events. One study, conducted by the 
Department of Veterans’ Affairs, compared varenicline to 
NRT and found no statistically significant difference in the risk 
of negative neuropsychiatric events at one month after being 
prescribed varenicline or NRT. This study did not specifically 
quantify suicidality or suicide rates. The second study was con-
ducted by the Department of Defense and found no excess of 
psychiatric hospitalizations at 30 or 60 days for patients being 
prescribed varenicline or NRT. It is possible that these stud-
ies did not capture all serious adverse events that did not lead 
to hospitalization. However, their value lies in the number of 
patients examined as well as the real-world setting that does 
not exclude medical or psychiatric comorbidities29
Meta-analyses of randomized controlled trials to date have 
not supported a correlation between neuropsychiatric adverse 
events and use of varenicline. Gibbons and Mann48 reana-
lyzed data from the 17 placebo-controlled RCTs (N = 8,027) 
of varenicline conducted by Pfizer to assess possible neuropsy-
chiatric adverse events. They found that varenicline increased 
the risk of nausea (OR 3.69, 95% CI 3.03−4.48) but not the 
rates of suicidal events, depression, or changes in behavior. 
A history of current or past psychiatric illness increased the 
risk of neuropsychiatric events equally in patients treated 
with varenicline and those receiving placebo. They also used 
a large Department of Defense (DOD) observational study 
(N = 35,800) to compare acute rates of neuropsychiatric adverse 
events in patients receiving varenicline or NRT. After propen-
sity score matching, the overall rate of neuropsychiatric adverse 
events was significantly lower for varenicline than for NRT. In 
a 2013 Cochrane review examining 14 varenicline trials, no 
difference was found in terms of serious adverse events (neu-
ropsychiatric or cardiac events) when comparing varenicline 
and placebo.29 Finally, in a recent review, Hughes49 examined 
post-marketing analyses, case reports, clinical trials, uncon-
trolled observational studies, controlled observational studies, 
and studies in smokers with psychiatric problems that have 
tested this association. Two pooled analyses of 10 and 17 
placebo-controlled trials failed to find more suicidal outcomes 
in the varenicline condition. Seven large uncontrolled observa-
tional studies reported low rates of suicide outcomes in vareni-
cline users (,0.1%), and one study reported a higher rate (6%). 
Five large controlled observational studies did not find more 
suicide outcomes in varenicline users than in those using pre-
scribed bupropion or over-the-counter nicotine medications. 
Small placebo-controlled trials and observational studies of 
smokers with current psychiatric problems did not find that 
varenicline was associated with suicidal outcomes.
Overall, it would appear that among the more valid study 
designs (pooled analyses of placebo controlled trials or large 
controlled observational studies), there is consistent evidence 
that varenicline either does not cause increased suicide out-
comes, or if it does, the effect is very small.
summary of pharmacotherapies. The research regard-
ing the use of pharmacotherapies for use in smoking cessation 
demonstrates often confusing and conflicting results regarding 
risks of depression, irritability, and suicidality. It appears that 
nicotine replacement therapies are more effective than place-
bos, equally effective to each other and to bupropion SR, but 
not as effective as varenicline. However, the risks of suicidality 
or other negative moods and behaviors appear to be lowest in 
NRT. Both bupropion SR and varenicline not only appear to 
have support for effectively facilitating smoking cessation but 
also carry low but increased risks for negative affect, behavior, 
and suicidality. Varenicline appears to have the most research 
support for increasing risks of suicidality, although the data are 
mixed and more recent well-controlled studies do not appear 
to support that varenicline demonstrates increased risk. Addi-
tional studies are currently underway under the direction of 
the FDA. A recent clinical trial, conducted by Pfizer (Study 
Evaluating The Safety and Efficacy of Varenicline and Bupro-
pion For Smoking Cessation In Subjects with and without a 
History of Psychiatric Disorders (EAGLES), clinicaltrials.gov 
identifier NCT01456936), is specifically designed to examine 
depression and other psychiatric events in varenicline users 
compared to users of bupropion, nicotine replacement, and 
placebo in people with and without prior psychiatric problems. 
Results are expected in 2017. Until that time, it would appear 
that NRT and bupropion may be the best option for first-line 
treatment approaches for smoking cessation, but that vareni-
cline should not be discounted or discouraged, but used with 
full disclosure to the patient.
Psychological Therapies
Psychological treatments such as cognitive behavioral therapy 
(CBT) and mindfulness-based approaches use strategies that 
are different from pharmacotherapy to help assist in smok-
ing cessation and may be used alone or in conjunction with 
pharmacotherapy. CBT is an evidence-based psychological 
treatment approach that focuses on identifying and chal-
lenging maladaptive thoughts, emotions, and behaviors that 
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may trigger or maintain a variety of difficulties, including 
depression, anxiety, and smoking. Through changing thoughts 
and behaviors, this treatment has been demonstrated to help 
improve mood symptoms and reduce cravings as well as facili-
tate smoking cessation.22,50 Mindfulness-based approaches to 
smoking cessation focus on helping the smoker develop a dif-
ferent relationship with triggers and cravings through devel-
opment of skills to increase awareness and presence in the 
moment without automatically reacting.51 Mindfulness-based 
strategies may also positively impact mood.52 There are mul-
tiple components and techniques involved in both CBT and 
mindfulness-based psychotherapies, and the research literature 
is not always clear on their definition of these interventions. 
Thus, in our review below, we examine studies that identi-
fied a CBT or mindfulness-based approach containing at least 
one of the core components of either CBT or a mindfulness 
approach, namely a focus on changing behavior, thoughts, or 
emotions in the case of CBT, or in the case of mindfulness, a 
focus on helping the patient become more aware of and being 
in the present moment including their urges/cravings and 
triggers, and learning how to be present in a nonjudgmental 
manner, as well as focus on changing their relationship with 
cravings or urges.
cognitive behavioral therapies. Cognitive behavioral 
therapies (CBTs) theorize that mental disorders, including 
mood and addiction disorders, are maintained by cognitive, 
emotional, and behavioral factors, although the etiology of 
such disorders may be multicausal, including genetic com-
ponents. Thus, in CBT, the treatment is focused on identify-
ing, arresting, challenging, and replacing these maladaptive 
or erroneous behaviors, emotions, and thoughts with more 
adaptive and effective ones, thus improving the symptoms or 
behaviors and ultimately the disorder.22,96 Many techniques are 
used, typically in a structured or manualized format, and often 
with a case formulation approach to tailor the treatment. There 
is a focus on behavioral modification techniques including 
extinction and development of new more adaptive healthy cop-
ing behaviors to replace smoking. CBT has a strong research 
literature demonstrating a positive impact on mood disorders 
such as depression53,54 and has demonstrated effectiveness in 
treating addiction in general,55 smoking specifically,50,56,57 and 
in smokers with co-morbid depression and other addictions.58
There are multiple components to a CBT approach to 
smoking cessation, and it typically contains preparation, quit-
ting, and maintenance or relapse prevention phases of treat-
ment. Initial mechanisms may include aspects of motivational 
interviewing to help promote readiness to change behavior. If 
motivational interviewing techniques are not employed in a 
patient who is not ready or motivated to change, CBT strat-
egies are hypothesized to be of limited value, since therapy 
typically involves the patient collaborating and working in 
setting goals and changing behavior and thinking.59 Cogni-
tive behavioral therapy focuses on facilitating and maintain-
ing change by a using a variety of behavioral and cognitive 
strategies. These include reducing cravings and withdrawal 
symptoms through repeated exposure to situational triggers 
(cognitive exposure therapy (CET), which gradually reduce 
symptoms and amount of smoking,60 reducing smoking crav-
ing through exercise (exercise assisted reduction then stop 
(EARS)),61 virtual exposure to negative cigarette behavior 
(virtual extinction)62 manipulating rewarding drug-related 
memories and reorganizing (extinction and reconsolida-
tion of memory),63 diverting attention from smoking visuals 
(attentional bias modification),64 and reducing negative inter-
nal judgments by using cognitive strategies to evaluate and 
revise self-statements, including thoughts that one cannot 
cope without a cigarette.65 Additional components of a CBT 
program may include providing information about tobacco, 
a behavioral contract through which the patients pledge to 
attend the sessions and quit smoking, self-monitoring and 
graphical representation of cigarette smoking, strategies for 
controlling nicotine withdrawal symptoms, physiological 
feedback (measured by CO and cotinine), training in alter-
native and/or competing behaviors, social reinforcement of 
objectives completion and abstinence, and relapse prevention 
strategies. Such psychotherapies provide addicted individu-
als various approaches to discontinue smoking, particularly 
emphasizing effective personal learning styles. Research sup-
ports that CBT is effective for a wide range of individuals 
who are trying to quit smoking, including PTSD patients,63 
people living with HIV,66 individuals with mental illness,67 
low socioeconomic smokers,57 adults with chronic pain,68 
overweight and disadvantaged smokers,61 and youth.65 CBT 
has been demonstrated to be more effective than NRT alone 
in promoting smoking cessation.56 CBT added to Contin-
gency Management, a purely behavioral reinforcement strat-
egy where smokers are rewarded for abstinence with vouchers 
that can be exchanged for rewards, has been demonstrated to 
be effective in reducing smoking and was also demonstrated 
to be more effective than CM alone.69 Rates of abstinence 
in these studies may double the rates of control groups when 
included. For example, the Sykes and Marks57 study describes 
a randomized-controlled trial of CBT with smokers from an 
underprivileged area of London. At six-month follow-up, 
21 (17.2%) of 122 participants receiving therapy were absti-
nent and 14 (11.5%) had reduced cigarette consumption by at 
least 25% of pre-treatment level. Six (5.6%) of 107 participants 
in the information only control group were abstinent and none 
had reduced consumption. CBT added to pharmacotherapy 
has also been demonstrated to improve compliance and reduce 
potential weight gain associated with smoking cessation70 as 
well as improve mood symptoms when combined with bupro-
pion in psychiatric populations trying to quit smoking.71 
Thus, CBT smoking cessation approaches may be appropriate 
choices, especially for those interested in drug-free smoking 
cessation strategies or those who wish to augment pharma-
cotherapy. CBT does not have the troublesome physical side 
effects of pharmacotherapy, but it does take motivation and 
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effort on the part of the patient, as well as access to trained 
providers, which must be taken into consideration.
The benefits of CBT appear to outweigh risks, and studies 
of CBT demonstrate improvement in depression, anxiety, and 
negative affect,65,72 which may directly or indirectly decrease 
suicidality risks associated with smoking cessation.67,73,97,98 
CBT has shown considerable success in reducing suicidal-
ity risk through reduction of hopelessness, suicidal ideation, 
and suicidal behavior.74 In a study examining the impact of 
CBT with or without an added component to address anxi-
ety, Capron et al.18 found that suicidality as assessed by the 
Inventory of Depression and Anxiety Symptoms75 was low-
ered in both groups, but was statistically significantly lower in 
the group receiving the augmented CBT. Unfortunately, the 
majority of CBT studies for smoking or nicotine cessation do 
not specifically describe how many participants report sui-
cidality after instigating therapy or post-treatment unless these 
data are reported as significant adverse events during the study, 
and these rarely make it into the manuscript. Thus, we have 
little information regarding the specific incidence of suicidal-
ity in patients who are trying to quit smoking by engaging in 
CBT only. We do know that the risk of suicide has shown to 
increase when smoking decreases, even for persons without 
prior psychopathology. For persons already possessing a his-
tory of mental illness, declines in smoking that lead to signifi-
cantly heightened anxiety, depression, and suicidal ideation are 
a concern. However, the majority of patients who successfully 
or unsuccessfully quit smoking using CBTs do not appear to 
increase their risk of psychopathology and are not at higher 
risk for suicidality.67
contextual cbts/mindfulness-based psychotherapies. 
Mindfulness-based therapies (sometimes referred to as con-
textual CBTs) focus on helping patients understand how 
thoughts, emotions, and body sensations trigger negative habits 
and cravings, and thus lead to psychological disorders. These 
treatment approaches hypothesize that by becoming more cog-
nizant or mindful of these potential triggers, patients are better 
able to avoid negative habits.51 A key difference between con-
textual CBTs and traditional CBT is the emphasis on mindful-
ness and acceptance strategies to reduce the impact of internal 
triggers on substance use behavior (eg, altering the context 
and function so cravings, distress, or thoughts of using are less 
likely to lead to substance use).76 These interventions include 
mindfulness-based smoking cessation and acceptance and com-
mitment therapy.
Mindfulness-based treatment approaches have been the 
most researched of the contextual CBTs for substance use 
and other psychiatric disorders. Mindfulness-based therapies 
have been demonstrated to help patients overcome psychiat-
ric disorders including anxiety and depression.77 While fur-
ther evidence is needed to better understand mindfulness as 
a component of treatment for substance use, recent reviews of 
the evidence indicate its efficacy for promoting abstinence and 
reducing cravings.51,78–80,95 Recently, research by Brewer et al.78 
demonstrated the effectiveness of mindfulness-based therapies 
by randomizing participants to either mindfulness therapy or 
an alternative empirically supported cognitive-based therapy 
called Freedom From Smoking or FFS.81 These researchers 
found that 36% of participants receiving mindfulness training 
achieved abstinence compared to 15% of participants in the 
alternative treatment group. After a 17-week follow-up, 31% 
of the mindfulness cohort remained abstinent compared to 
just 6% of participants receiving the alternative. Brewer et al.78 
concluded that mindfulness training is an effective method to 
help people quit smoking. These authors further promote that 
the 17-week point prevalence odds ratio of 6.75 in their mind-
fulness-based intervention group was significantly larger than 
the average odds ratio of behavioral therapies as reported in 
the current clinical practice guidelines, such as those target-
ing negative affect (OR = 1.2, abstinence rate = 13.6%), social 
support (OR = 1.5, abstinence rate = 16.2%), practical coun-
seling (OR = 1.5, abstinence rate = 16.2%), aversive smok-
ing (OR = 1.7, abstinence rate = 17.7%), and medication + 
counseling (OR = 1.7, abstinence rate = 22.1%).82
Tang et al.83 also found a mindfulness-based therapy 
to be an effective treatment for smoking cessation. Tang 
divided participants into two cohorts: (1) integrative body-
mind training (IBMT), which is a contextual or mindfulness 
based psychotherapy focused on implementing meditation 
or (2) traditional relaxation training. Participants receiving 
IBMT reduced their smoking habits by 60% by the study’s 
end, whereas there was no demonstrated reduction in the 
relaxation group. Brain scans revealed that participants in 
the IBMT cohort also experienced increased activity in the 
parts of the brain responsible for self-control. Tang et al.83 
concluded that mindfulness training increases smokers’ self-
control and reduces the likelihood that smokers will act on 
their cravings.
Recently, several randomized controlled trials (RCTs) 
have suggested Acceptance and Commitment Therapy (ACT) 
as another promising contextual CBT for substance use.76,84 
While ACT includes mindfulness as a treatment component, 
its approach differs from other mindfulness-based treatments 
in that the concept of mindfulness within ACT is tightly inte-
grated with other processes of change such as acceptance, val-
ues, and behavior change methods and ACT protocols often 
include a less heavy emphasis on meditative practices. ACT 
uses a combination of acceptance, mindfulness, and values-
based therapeutic processes to foster psychological flexibil-
ity, which involves learning how to mindfully observe inner 
experiences such thoughts, feelings, and bodily sensations 
but not necessarily react to them. There is a focus in ACT 
on discovering values to guide thoughts and behavior.84 As 
applied to substance use disorders, patients are taught accept-
ing and mindful ways of relating to inner experiences, rather 
than engaging in substance use (eg, in response to cravings 
or escape negative affect), while moving forward in building 
meaningful patterns of activity that are further inconsistent 
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with substance use. Because of the transdiagnostic nature of 
ACT, it can effectively target common comorbid psychologi-
cal disorders such as depression and anxiety.85–87 Lee et al.76 
conducted a meta-analysis that included 10 studies, of which, 
five were smoking cessation outcome studies and included an 
N of 918. All studies employed ACT and compared it to other 
active empirically supported treatments including CBT and 
NRT or bupropion. Lee et al.76 found a small-to-medium sig-
nificant effect size favoring ACT over other active treatments 
(g = 0.42, 95% CI = 0.19, 64, z = 3.64, P , 0.001, k = 5).
A study by Ruscio et al.88 evaluated the impact of a brief 
mindfulness intervention versus a control condition, upon 
affect, craving, and smoking behavior and employed eco-
logical momentary assessment to gather real time data. Based 
on results from 37 participants, for the intervention group, 
she reports significant reductions in overall negative affect, 
F(1, 1798) = 13.8, P = 0.0002; reduced craving immediately 
post-meditation, (Group × Assessment Type interaction, 
F(2, 1796) = 12.3, P = 0.0001); and reduced cigarettes smoked 
per day over time (Group × Day interaction, F(1, 436) = 5.50, 
P = 0.01). Suicidality was not assessed directly, but it may be 
inferred that reductions in negative affect may reduce sui-
cidality risks. Unfortunately, mindfulness based or contextual 
CBTs for smoking cessation have even less published research 
on the impact of suicidality than CBT and most studies do 
not include information about suicidality.
summary of psychotherapies. Research appears to sup-
port significant success rates for smoking cessation and 
smoking reduction for CBT. CBT appears to be an effec-
tive drug-free option to consider for individuals looking to 
reduce and/or quit smoking and may also successfully be 
used in conjunction with pharmacotherapy.50,56,57 Addition-
ally, although relatively new to the scene and many studies do 
not specifically address this issue, contextual CBTs such as 
mindfulness-based therapy and ACT appear to demonstrate 
success in treating nicotine addiction and promoting smok-
ing cessation with minimal or no reported increased risk of 
suicidality.76,78,88 CBT, mindfulness-based interventions, and 
ACT have a documented research history of reducing depres-
sive symptoms, and CBT has been demonstrated to help 
reduce suicidality in smokers trying to quit.18 There is less 
known about the benefits of each of these psychotherapies in 
reducing risk of suicidality in active smokers who are trying 
to reduce or quit their intake, and many studies implementing 
psychotherapy in the smoking population do not report data 
regarding suicidality.
No treatment
Although numerous clinical trials support medical and behav-
ioral interventions as successful tools for smoking cessation, 
a significant proportion of the smoking population chooses 
to opt for an unassisted approach by abruptly stopping their 
smoking patterns altogether. In fact, almost two-thirds of all 
people seeking to quit try this cold turkey method.89 Despite 
the large number of individuals who attempt to quit smoking 
unassisted, research supports that unassisted quitting methods 
are less effective than medical or psychological therapies. In 
one population study surveying 10,355 individuals, research-
ers found that those using medication in combination with 
behavioral therapies were, on average, three times more likely 
to stay quit and remain abstinent than those not using any 
cessation interventions.90 In another study, abstinence rates 
for unassisted quitters were about 7% compared to 15.2% for 
quitters assisted with counseling methods and various thera-
pies.91 Researchers Baillie et al.92 established a baseline absti-
nence rate for unassisted individuals of 7.33%, consistent with 
Kotz et al.90 study.
The above findings are significant when considering 
the connection between smoking cessation and suicidality. 
Numerous studies have linked nicotine dependence and with-
drawal to depression, with nicotine-dependent individuals 
being more than twice as likely to experience a major depressive 
disorder than those without a nicotine dependence history.5 
Because depression is linked to increased risk of suicidality, 
and because those who quit smoking cold turkey will likely 
have a more difficult time dealing with nicotine withdrawal 
symptoms than those who are part of a longer-term interven-
tion program, unassisted individuals are possibly at a higher 
risk for depression and suicidality.16 These are important fac-
tors to consider when planning an optimal intervention for 
smoking cessation.
conclusions
In this paper, we briefly reviewed the most frequently uti-
lized treatments for smoking cessation, focusing not only 
on the ability of the treatment to impact smoking reduction 
and cessation but also on the connection between the treat-
ment and reduction in risk of suicidality. Current smoking 
is associated with an increased risk of suicidality.2,93 Several 
treatment options are available to assist individuals wishing 
to quit smoking, including various pharmacotherapies and 
psychotherapies. Unfortunately, such treatments rarely come 
without any side effects or caveats. Pharmacotherapies of any 
kind typically have side effects other than the intended effect 
and smoking cessation medications are no different. There 
have been mixed results regarding the increased risk of sui-
cidality with the use of certain pharmacotherapies for smok-
ing cessation. Some medications for smoking cessation may 
also be expensive and thus not available for patients. Therapy 
is not without limitations, including possible negative effects 
such as the potential for revealing additional psychological 
trauma or issues that may worsen other symptoms when the 
patient is trying to focus on smoking cessation. Additionally, 
psychotherapy requires that patients seek and comply with 
treatment and that they are motivated to engage and work to 
change behavior. Trained practitioners have also traditionally 
provided psychotherapy and patients may not always be able 
to find a qualified practitioner who is affordable and available 
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to provide treatment. Thus, the question of which smoking 
reduction or cessation treatment approach may be effective in 
promoting smoking cessation while causing the least risk is 
challenging to determine. Internet and online treatments are 
growing in popularity but knowledge of their impact or effi-
cacy in helping reduce smoking or promote cessation is less 
well studied at this time. The connections between smok-
ing cessation treatments and increased risk of suicidality are 
complex and sometimes contradictory, as has been reviewed 
in the present article. Both bupropion and varenicline appear 
to have support for effectively facilitating smoking cessation, 
but early research supported an increased risk for negative 
affect, behavior, and suicidality. Varenicline appears to have 
the most research support for increasing risks of suicidality 
although the data is mixed and more recent well-controlled 
studies do not appear to support that varenicline demon-
strates increased risk. In more recent studies, these medica-
tions appear to demonstrate no increased risk of suicidality. 
Reasons for these mixed findings may include having more 
well-controlled studies currently, as opposed to the past. The 
fact that recent studies appear to exclude patients with seri-
ous depression or history of suicidality, who would presum-
ably be at greater risk for suicidality during the treatment 
trial and/or when quitting smoking, may also play into the 
recent findings of less increased risk of suicidality with these 
medications in more recent research. Psychotherapies such 
as CBT do not appear to have a significant risk of increasing 
suicidality and appear to work at least moderately effectively 
to help reduce or quit smoking. In early research findings, 
the newer psychotherapies such as contextual mindfulness 
based CBTs also appear to demonstrate at least moderate 
effect on smoking cessation. Although these mindfulness 
based treatments also appear to have a positive impact on 
mood symptoms such as depression, there is currently little 
research regarding their impact on reducing suicidality in 
individuals trying to quit smoking. Given that pharmaco-
therapy has been shown to be the most effective interven-
tion for increasing the odds of success in smoking cessation, 
but may increase the risk of suicidality, even modestly,20,28 
it may be that the combination of cognitive and/or behavior 
therapy plus pharmacotherapy could have a synergistic effect 
of improving quit success rates, while also providing protec-
tion from any increased risk of suicidality.90
Further development and refinement of treatments to 
help promote smoking cessation are necessary and vitally 
important if we are to positively impact the overall health 
of millions of people addicted to nicotine. Smoking cessa-
tion can be aided by employing effective pharmacotherapies 
and psychotherapies, but the risks of such treatments must be 
examined and balanced against the benefits. Future research 
should continue to explore and document possible correla-
tions and causal relationships between various therapies for 
smoking cessation and increased risk of suicidality as well as 
positive impact. It may be useful to further evaluate which 
patients demonstrate increased risk for suicidality during 
clinical trials. For instance, in some research reports, when 
the circumstances of the suicidal behavior where investigated, 
it was discovered that the patient was responding to traumatic 
events or had a history of severe depression prior to going on 
the medications. Many of the psychotherapy studies have not 
documented suicidality and this should be addressed in future 
studies. Exploration of the impact of combination treatment 
should also include replication studies of clinical trails as well 
as studies of the impact of psychotherapy on reducing depres-
sive symptoms during smoking cessation, preferably including 
well-powered randomized trails with long-term follow-up and 
processes of change analysis.
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